Clinical Trial

Evaluation of Safety and Efficacy in BEY1107 in Monotherapy Gemcitabine Combination in Patient with Pancreatic Cancer

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This study is a single center, open-label, non-comparative, phase I/II clinical trial to assess the maximum tolerated dose (MTD), safety and efficacy of BEY1107 in monotherapy and in combination with gemcitabine in patient With locally advanced or metastatic pancreatic cancer.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2018-07-05; most recent amendment 2025-03-06.
Trial Details
NCT Number NCT03579836
Lead Sponsor BeyondBio Inc.
Conditions Locally Advanced or Metastatic Pancreatic Cancer
Enrollment 75 participants
Start Date 2018-05-14
Primary Completion 2026-11-30 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-03-10